Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor's therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
The reverse-merger was announced five months ago, and shareholders approved the combination yesterday.
CHAQ will begin trading as RCOR at the open tomorrow.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”